Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamibarotene in Heart Failure With Preserved Ejection Fraction (RELIEF)
NCT07855692Phase 2Recruiting
- Sponsor
- Nagoya University
- Start
- Oct 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
A Phase 2 trial of tamibarotene in heart failure with preserved ejection fraction (HFpEF), sponsored by Nagoya University. Started Oct 2026; status: recruiting.
02
Drugs
tamibarotene
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT07855692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07855692.